Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

WATERTOWN, Mass., August 21, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage ...

Enanta (ENTA) announced that it has filed suit in the Unified Patent Court of the European Union against Pfizer (PFE) and certain of its ...

Enanta Q2, 2022 Earnings Presentation (ir.enanta.com) Since its 2017 approval, Glecaprevir generated royalties totaling $722 million per Enanta's fiscal year ending 09/2021 10-K.

Enanta argued that symptom improvement was similar for both antivirals. EDP-235 could be developed and tested in several COVID-related indications, such as long COVID or as a prophylaxis, Luly said.

Enanta could also sell royalties on EDP-494 or EDP-305. With its funding in place, there isn't a real need for Enanta to risk share this so I see this as unlikely.

Enanta Pharmaceuticals, inc (ENTA 2.55%) Q4 2021 Earnings Call Nov 22, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good ...

Enanta Pharmaceuticals Inc., (Nasdaq: ENTA), whose lead drug candidate is in late-stage trials for hepatitis C, has received a $9.2 million boost for its preclinical program focused on a new form ...